Abstract
Background
Severe alcoholic hepatitis (AH) has a poor short-term prognosis often caused by infections. However, the incidence of invasive mycosis in patients with AH treated with corticosteroids and its impact still remains unknown.
Methods
Retrospective analyses of twelve medical ICU patients (out of 120 patients with liver cirrhosis) with histological proven AH.
Results
Twelve patients were diagnosed with histological proven AH during there stay at the ICU. All patients were treated with corticosteroids; three patients were treated with corticosteroids and pentoxifylline. Five patients had invasive aspergillosis (IA); three patients had candidemia; and two had fungal colonization with candida species. Only two patients had no evidence for fungals. IA was associated with death in all cases. Death occured in most cases shortly after diagnosis despite antifungal medication. Two patients with candidemia died; one patient died in the group with fungal colonization. Overall, the mortality rate was 100 % in patients with IA and 70 % in the group with candidemia.
Conclusions
Patients with severe AH have an increased susceptibility to invasive mycosis associated with high mortality. A high level of suspicion of invasive mycosis in AH patients and prophylactic strategies are needed in those patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–69.
Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480–7.
Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137:541–8.
Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56:S1–12.
Segal BH. Aspergillosis. N Engl J Med. 2009;360:1870–84.
Prodanovic H, Cracco C, Massard J, Barrault C, Thabut D, Duquet A, et al. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol. 2007;7:2.
Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol. 2011;49:406–13.
Singh N, Husain S. The AST infectious Diseases Community of Practice: invasive aspergillosis in solid organ transplant recipients. Am J Transplant. 2009;9:S180–91.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.
Spriet I, Meerssemann W, Annaert P, de Hoon J, Willems L. Pharmacokinetics of caspofungin in a critical ill patient with liver cirrhosis. Eur J Clin Pharmacol. 2011;67:753–5.
Traunmuller F, Popovic M, Konz KH, Smolle-Juttner FM, Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology. 2011;88(213–224):12.
Conflict of interest
None of the authors has any potential financial conflict of interest related to this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Tobias Lahmer and Marlena Messer have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Lahmer, T., Messer, M., Schwerdtfeger, C. et al. Invasive Mycosis in Medical Intensive Care Unit Patients with Severe Alcoholic Hepatitis. Mycopathologia 177, 193–197 (2014). https://doi.org/10.1007/s11046-014-9740-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11046-014-9740-x